Ray, K.K., Troquay, R.P.T., Visseren, F.L.J., Leiter, L.A., Scott Wright, R., Vikarunnessa, S., et al. (2023) Long-Term Efficacy and Safety of Inclisiran in Patients with High Cardiovascular Risk and Elevated LDL Cholesterol (ORION-3): Results from the 4-Year Open-Label Extension of the ORION-1 Trial. The Lancet Diabetes & Endocrinology, 11, 109-119.
https://doi.org/10.1016/s2213-8587(22)00353-9

has been cited by the following article:

• TITLE: Postponing AMI to 100 Years: An Emerging Concept

  AUTHORS: Prabhash Chand Manoria

  KEYWORDS: Acute Myocardial Infarction, Cumulative Exposure of LDL-C, Inclisiran, CRISPR Technology

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.14 No.6, June 27, 2024

  ABSTRACT: Acute myocardial infarction is a deadly disease, and in the Indian context, it occurs at a younger age, even below the age of 40 years, and sometimes even below 30 years. These young MI patients have high mortality rates, and many of them are not able to reach the hospital. The pathophysiology of AMI is very well understood. AMI is a multifactorial disease and has several risk factors, like dyslipidemia, diabetes, hypertension, smoking, diet, etc. However, low-density lipoprotein cholesterol (LDL-C) has a very strong causal relationship with atherosclerosis. Reducing LDL-C to